Providence Therapeutics Reports PTX-COVID19-B, its mRNA Vaccine for COVID-19, Neutralizes SARS-CoV-2 and Variants of Concern, Including Delta

PTX-COVID19-B dosed subjects from the Phase 1 clinical trial have high neutralization titers against the original strain of SARS-CoV-2 (G614). All subjects produced neutralizing antibodies after the first dose and the levels increased more than 10-fold after the second dose. The responses...

from PR Newswire: https://ift.tt/3hu4kX0